Enzon Pharmaceuticals, INC. (ENZN) — 10-Q Filings

10-Q Filings (6)

• Enzon's Losses Mount Amid Zero Revenue, Viskase Merger Costs — Nov 12, 2025 Risk: high
  Enzon Pharmaceuticals, Inc. (ENZN) reported a net loss of $824,000 for the three months ended September 30, 2025, a significant increase from the net income of
• Enzon's Q2 Losses Mount Amid Zero Revenue, Viskase Merger Costs — Aug 14, 2025 Risk: high
  Enzon Pharmaceuticals, Inc. reported a significant decline in financial performance for the three and six months ended June 30, 2025. Total revenues plummeted t
• Enzon Pharmaceuticals Files Q1 2025 10-Q — May 9, 2025 Risk: low
  Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial
• Enzon Pharma Files 3Q 2024 10-Q — Nov 5, 2024 Risk: low
  Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial information and business operations. Key finan
• Enzon Pharmaceuticals Files Q2 2024 10-Q Report — Aug 8, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the second
• Enzon Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: low
  ENZON PHARMACEUTICALS, INC. (ENZN) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Enzon Pharmaceuticals, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX